首页> 外文OA文献 >Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies

【2h】

Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies

机译：尿激酶纤溶酶原激活剂及其抑制剂PAI-1，作为乳腺癌中的预后标志物：从飞行员到1级证据研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Michael J Duffy;
展开▼
作者单位

展开▼
年度 2002
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies [J] . Michael J. Duffy Clinical Chemistry: Journal of the American Association for Clinical Chemists . 2002,第8期

机译：尿激酶纤溶酶原激活剂及其抑制剂PAI-1作为乳腺癌的预后标志物：从试验到1级证据研究
2. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors [J] . Maja Lampelj, Darja Arko, Nina Cas-Sikosek, Radiology and Oncology . 2015,第4期

机译：乳腺癌中尿激酶纤溶酶原激活物（uPA）和纤溶酶原激活物抑制剂1型（PAI-1）-与传统预后因素的相关性
3. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study. [J] . Jelisavac Cosic S, Sirotkovic Skerlev M, Kulic A, Tumori. . 2011,第4期

机译：尿激酶型纤溶酶原激活物（uPA）和纤溶酶原激活物抑制剂（PAI-1）在原发性浸润性导管癌患者中的预后意义-一项为期7.5年的随访研究。
4. Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells In Vitro and In Vivo [C] . Viktor Magdolen International Meeting on Molecular Staging on Cancer . 2003

机译：抑制肿瘤相关的尿激酶型纤溶酶原激活系统：高水平合成在体外和体内卵巢癌细胞中可溶性尿激酶受体的影响
5. Evaluation of 14-1B mutant of recombinant human plasminogen activator inhibitor type 1 (PAI-1) as a potential anti-angiogenic and anti-cancer agent. [D] . Swiercz, Rafal. 2001

机译：评价重组人纤溶酶原激活物抑制剂1型（PAI-1）作为潜在的抗血管生成和抗癌剂的14-1B突变体。
6. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors [O] . Maja Lampelj, Darja Arko, Nina Cas-Sikosek, 2015

机译：乳腺癌中尿激酶纤溶酶原激活物（uPA）和纤溶酶原激活物抑制剂1型（PAI-1）-与传统预后因素的相关性
7. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors [O] . Lampelj Maja, Arko Darja, Cas-Sikosek Nina, 2015

机译：乳腺癌中尿激酶型纤溶酶原激活物（upa）和纤溶酶原激活物抑制物-1型（paI-1） - 与传统预后因素的相关性

Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies

著录项

引文网络

相似文献

相关主题

期刊订阅